These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8795592)

  • 1. More immunotherapy for multiple sclerosis.
    Hughes RA; Sharrack B
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592
    [No Abstract]   [Full Text] [Related]  

  • 2. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 3. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of magnetic resonance imaging studies in multiple sclerosis.
    Cerreta E
    J Neurosci Nurs; 1998 Oct; 30(5):290-301. PubMed ID: 9816560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 6. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 7. Options for multiple sclerosis therapy.
    Cotton P
    JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatments for multiple sclerosis.
    McDonald WI
    BMJ; 1995 Feb; 310(6976):345-6. PubMed ID: 7866205
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy in multiple sclerosis.
    Tullman MJ; Lublin FD
    Curr Neurol Neurosci Rep; 2005 May; 5(3):245-8. PubMed ID: 15865891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 12. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 14. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 15. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 16. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment and treatment trials in multiple sclerosis.
    Kieseier BC; Wiendl H; Hemmer B; Hartung HP
    Curr Opin Neurol; 2007 Jun; 20(3):286-93. PubMed ID: 17495622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and therapy in multiple sclerosis].
    Sailer M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 May; 45(5):328-34. PubMed ID: 20455189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Unresolved problems and the prospects for research in area of the multiple sclerosis: virologic, immunologic and therapeutic aspects].
    Mal'tsev DV
    Lik Sprava; 2014; (5-6):3-19. PubMed ID: 25906643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.